Foster Karen A., Chief Quality and Operations officer, has demonstrated a consistent pattern of selling shares in BioLife Solutions Inc. (BLFS) over the past two years, with no recorded purchases. According to SEC Form 4 filings, Foster has executed 31 transactions totaling $2.63 million in sales, with 20 of those occurring in the most recent period. The largest single sale took place on March 5, 2026, when Foster disposed of shares worth $1.95 million, significantly outweighing smaller transactions such as the $49,401 sale on March 23, 2026, or the $8,669 transaction on March 3, 2026. Earlier activity included periodic sales, like the $29,474 disposition on February 24, 2026, and a series of smaller sales throughout 2025 and 2024, typically ranging between $1,000 and $30,000 per transaction.
The filings also indicate several awards (coded "A") with no reported value, suggesting equity grants rather than open-market purchases. Foster’s trading history is exclusively tied to BLFS, with no diversification across other companies. The absence of buying activity and the sustained selling trend—particularly the accelerated pace in early 2026—reflect a clear divestment strategy. While the reasons for these sales are undisclosed, the data underscores a one-directional reduction in Foster’s holdings in BioLife Solutions over time.
AI-assisted summary